 PRINCETON, N.J., May 10, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that HyBryteTM hypericin was awarded an Innovation Passport for the treatment of early stage cutaneous T-cell lymphoma CTCL in adults under the United Kingdoms UKs Innovative Licensing and Access Pathway ILAP. 